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Abstract
 
Rapid clearance of pathogens is essential for successful control of pyogenic bacterial infection.
Previous experiments have shown that antibody to specific intracellular adhesion molecule-
grabbing nonintegrin (SIGN)-R1 inhibits uptake of capsular polysaccharide by marginal zone
macrophages, suggesting a role for SIGN-R1 in this process. We now demonstrate that mice
lacking SIGN-R1 (a mouse homologue of human dendritic cell–SIGN receptor) are signifi-
cantly more susceptible to 
 
Streptococcus pneumoniae
 
 infection and fail to clear 
 
S. pneumoniae
 
 from
the circulation. Marginal zone and peritoneal macrophages show impaired bacterial recognition
associated with an inability to bind T-independent type 2 antigens such as dextran. Our work
represents the first evidence for a protective in vivo role for a SIGN family molecule.
Key words: DC-SIGN • marginal zone macrophages • microbial infection • 
innate immunity • lectin
 
Introduction
 
Pathogen recognition by the immune system is crucial for
the maintenance of protective immunity. Pattern recognition
receptors (PRRs), including C-type lectins and Toll-like
receptors, discriminate molecular patterns expressed by
pathogens and facilitate differential recognition of pathogens
and microbial products (for review see reference 1). These
innate immune responses provide a critical, rapid defense
mechanism that acts before the maturation of acquired immu-
nity. However, there are occasions when PRRs become
hijacked by pathogens and used to facilitate infection and
circumvent immune detection. A recently identified example
of this phenomenon is HIV-1 and Dengue virus usurping
DC-specific intracellular adhesion molecule-grabbing non-
integrin (DC-SIGN; CD209) and DC-SIGNR molecules
to facilitate infection (for review see reference 2). There-
fore, these SIGN molecules appear to represent an immu-
nological liability. This raises an unresolved question: what
positive role, if any, do the SIGN molecules play in protec-
tive immunity?
Human DC-SIGN is expressed on the surface of human
dendritic cells and is believed to play a key role in the initial
interaction between DCs and naive T cells through interac-
tion with ICAM-3 (3). However, it has also been demon-
strated that HIV-1 exploits DC-SIGN, using it as a receptor
to facilitate viral transport via DCs from mucosal surfaces to
CD4
 
 
 
 T cells in secondary lymphoid tissue (4) through its
lectin domain interacting with gp120 (5, 6). Recent studies
have also highlighted a role for DC-SIGN in the infection
of DCs by Ebola virus (7), human cytomegalovirus (8),
 
Leishmania pifanoi
 
 (9), 
 
Mycobacterium tuberculosis
 
 (10), and
Dengue virus (11). After the description of DC-SIGN, the
closely related molecule DC-SIGNR (DC-SIGN2, L-SIGN)
was reported, with its gene mapping within a few tens of
 
A. Lanoue and M.R. Clatworthy contributed equally to this work.
Address correspondence to Andrew N.J. McKenzie, Laboratory of
Molecular Biology, Medical Research Council, Hills Rd., Cambridge
CB2 2QH, England, UK. Phone: 44-1223-402350; Fax: 44-1223-412178;
email: anm@mrc-lmb.cam.ac.uk
M.J. Townsend’s present address is Dept. of Immunology and Infec-
tious Diseases, Harvard School of Public Health, Rm. 205, 651 Hunting-
don Ave., Boston, MA 02115.
 
Abbreviations used in this paper:
 
 aa, amino acids; CRD, carbohydrate rec-
ognition domain; MZ, marginal zone; MZM, MZ macrophage; PC,
phosphorylcholine; PRR, pattern recognition receptor; SIGN, specific
intracellular adhesion molecule-grabbing nonintegrin; TI-2, thymus in-
dependent type 2. 
SIGN-R1 Protects against Lethal Pneumococcal Infection
 
1384
kilobases of both DC-SIGN and CD23 (another C-type
lectin; references 12, 13). DC-SIGNR has also been shown
to bind HIV-1 (14) and Dengue virus (11), and it has been
suggested that its expression on liver sinusoidal endothelial
cells may facilitate clearance of antigenic proteins from the
circulation (15).
The mouse genome encodes five DC-SIGN homologues
that all map close to the mouse CD23 gene on mouse chro-
mosome 8 (16–18). These mouse genes have been termed
DC-SIGN and SIGN-R1–SIGNR4, with DC-SIGN map-
ping closest to CD23 as in the human (16). The mouse
DC-SIGN family contains highly homologous carbohydrate
recognition domains (CRDs), but the individual members
differ in the numbers of neck repeats or the presence of a
transmembrane domain (16). Expression studies also suggest
that these molecules are differentially expressed in various
tissues, suggesting that they may play tissue-specific roles
(16–18). It is noteworthy that mouse DC-SIGN has been
reported to be highly expressed by splenic DCs in a manner
similar to that described for human DC-SIGN, whereas the
other homologues are not as highly represented in the splenic
DC compartment (16–18). Furthermore, recent studies have
reported that, despite their having related mannose-binding
motifs, the various mouse SIGN molecules display differen-
tial ligand specificity with the potential to recognize differ-
ent pathogens (19, 20).
The highly organized microarchitecture of the spleen is
intimately involved with the effective clearance of patho-
gens by the immune system. The spleen is divided into re-
gions of white and red pulp separated by the marginal
zones (MZs). The cellular composition of the marginal
zone includes reticular cells, MZ B cells, DCs, metallo-
philic macrophages, and MZ macrophages (MZMs). It is in
the MZ that the blood flow is slowed down, as the termi-
nal arterioles open into venous sinuses, producing an envi-
ronment for the efficient entrapment of blood-borne parti-
cles by resident phagocytes (21). The MZMs are highly
phagocytic cells that are found in layers dispersed through-
out the MZ and are defined by their expression of the cell
surface molecules recognized by the antibodies ER-TR9
and MARCO (22, 23). Selective depletion of MZMs
and metallophilic macrophages using clodronate liposomes
identified that these cells are essential for trapping of mi-
crospheres and 
 
Listeria monocytogenes
 
 (24). Furthermore,
MZMs have been identified as critical phagocytes for the
uptake of neutral polysaccharides, such as Ficoll and dex-
tran, which represent thymus independent type 2 (TI-2)
antigens (25). Significantly, this uptake has been demon-
strated to be inhibited by the ER-TR9 antibody (26). A
recent paper from Kang et al. has indicated that antibody to
SIGN-R1 can also inhibit capsular polysaccharide uptake
by MZMs, but was unable to inhibit MZM uptake of
pneumococci, leading the authors to suggest that SIGN-
R1–independent recognition systems exist (27). SIGN-R1
expression has also been demonstrated on peritoneal mac-
rophages, and in vitro assays suggest that they may play a
role in mannose-mediated nonopsonic recognition of yeast
cells (28). Significantly, peritoneal macrophages are strate-
gically located to play an important role in protection
against bacterial infection, acting as phagocytes and produc-
ing proinflammatory cytokines.
Little is known regarding the biological function of
SIGN molecules. Given the subversion of human DC-
SIGN and DC-SIGNR by several human pathogens, we
wished to determine whether the SIGN-R1 molecule rep-
resents an immunological liability or a functionally protec-
tive immunoreceptor in vivo. To achieve this goal, we
generated SIGN-R1
 
   
 
 
 
mice using homologous recombi-
nation. MZMs from the SIGN-R1
 
   
 
 mice do not stain
with ER-TR9 and fail to bind the TI-2 antigen dextran.
Significantly, we demonstrate that SIGN-R1 is critical for
survival after infection with the gram-positive bacterial
pathogen 
 
Streptococcus pneumoniae
 
. SIGN-R1 binds 
 
S. pneu-
moniae
 
, facilitating efficient phagocytosis and bacterial clear-
ance, leading to protection against septicemia.
 
Materials and Methods
 
Cloning of Mouse SIGN-R1. 
 
EST accession no. AI386429
(IMAGE clone 597911) was identified as homologous to mCD23
and human DC-SIGN. Oligonucleotide primers (5
 
 
 
-ATCTCCC-
AAGGGAAGAATGAGTCC-3
 
 
 
 and 5
 
 
 
-CTGCAGGAAGGTC-
TGCTCTTCATC-3
 
 
 
) were generated using this EST sequence in-
formation and tested for the generation of DNA product from
mouse genomic DNA. These primers produced a PCR product that
was subcloned, sequenced, and used as a probe to screen mouse
PAC genomic library RPCI-21 (HGMP UK; reference 29).
RPCI-21 clone 424-C19 was identified and shotgun cloned after
BamHI restriction digest into pUC or pBluescript. These colonies
were rescreened for hybridization, and positives were sequenced us-
ing transposon integration (Genome Priming System; Biolabs). The
genomic sequence was completed using sequence deposited in the
public database from BAC clones RPCI-23-186C23 (accession no.
AC073706) and RPCI-23-458N3 (accession no. AC073804).
The mouse SIGN-R1 cDNA was generated by PCR using oligo-
nucleotides 5
 
 
 
-CACCAGGGGACAGCGGCAACC-3
 
 
 
 and 5
 
 
 
-
CTAGCCTTCAGTGCATGGGGTTGC-3
 
 
 
 with cDNA reverse
transcribed from total splenocyte RNA as template.
 
Targeted Disruption of the Mouse SIGN-R1 Gene in ES Cells.
 
The targeting vector consisted of a 2.2-kb 5
 
 
 
 arm of homology
and a 3.8-kb of 3
 
 
 
 homology. The replacement vector was con-
structed to insert the arms of homology on either side of a 
 
lox
 
P-
flanked neomycin resistance gene. The 5
 
 
 
 arm of homology was
generated by PCR using primers 5
 
 
 
-CATTCAAGTGCGGC-
CGCATTCTAACCCCAGC-3
 
 
 
 and 5
 
 
 
-AATGTCGGATC-
CCAGGGGCAGAGTCGACACAGG-3
 
 
 
 to give a NotI site
at the 5
 
 
 
 end and a BamHI site at the 3
 
 
 
 end. The 3
 
 
 
 arm of ho-
mology was generated by PCR using primers 5
 
 
 
-CATCATCTA-
GAGTGATGAAGAGCAGGTACATTTAGTG-3
 
 
 
 and 5
 
 
 
-
CTACAATCTAGAATTGTACGTCAAATAATCC-3
 
 
 
 to give
XbaI sites at either end of the fragment. The targeting vector was
linearized with NotI and electroporated into E14.1 ES cells (30).
Of 396 G418 resistant clones screened by Southern analysis, using
a probe (probe A) produced with PCR primers (5
 
 
 
-GTG-
AGAAAGCAGCAGTCCAAGC-3
 
 
 
 and 5
 
 
 
-TCAAATCTTCA-
GGCCCTCCAG-3
 
 
 
), 3 were targeted correctly. Hybridization
with a probe to the neomycin sequence confirmed the predicted
size of the targeted fragment and that only a single integration
had occurred. Targeted ES cells were microinjected into 3.5-d 
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C57BL/6 blastocysts to generate chimeras. These mice were
mated with C57BL/6 mice and transmitted the ES cell genotype
through the germline. Mice homozygous for the disrupted SIGN-
R1 gene were obtained by interbreeding the heterozygotes.
Genotyping was undertaken routinely using a PCR screening
protocol in which three oligonucleotides were combined in a sin-
gle reaction tube to identify wild-type and targeted alleles.
The oligonucleotides were 5
 
 
 
-CTATCAGGACATAGCGTTG-
GCTACC-3
 
 
 
, 5
 
 
 
-GCAGGAGAAGATCTACCAACAGCTG-3
 
 
 
,
and 5
 
 
 
-GAAGAAGTAACAATTTCCTAGGAG-3
 
 
 
 and result in
the generation of a 550-bp fragment from the wild-type allele and
a 750-bp product from the targeted allele containing the neomy-
cin gene. The SIGN-R1
 
   
 
 and wild-type animals used in these
experiments were maintained on a 129 
 
 
 
 C57BL/6 (F
 
2
 
) back-
ground in a specific pathogen-free environment in accordance
with UK Home Office guidelines. All animal experiments out-
lined in this paper were undertaken with the approval of the UK
Home Office or the Department of Health and Children, Ireland.
 
Detection of SIGN-R1 RNA Transcripts in Spleen. 
 
Total RNA
was prepared from splenocytes using RNAzolB. RT-PCR primers
for mouse SIGN-R1 were 5
 
 
 
-CTGAAAACTGAACTCTTGTC-
CAGG-3
 
 
 
 and 5
 
 
 
-CTGCTGCAGGAAGGTCTGCTC-3
 
 
 
. The
internal oligonucleotide used for hybridization was 5
 
 
 
-CAGCTGG-
TACAGATGAAGACTG-3
 
 
 
. HPRT primers and conditions were
as described previously (31). Additional SIGN-R1 primers were:
880, 5
 
 
 
-CTCCTAGGAAATTGTTACTTCTTC-3
 
 
 
; 969, 5
 
 
 
-
ATGAGTGACTCCACAGAAGCC-3
 
 
 
; 1175, 5
 
 
 
-CTAGCCT-
TCAGTGCATGGGGTTGC-3
 
 
 
; 1266, 5
 
 
 
-CTGAAAACTGAA-
CTCTTGTCCAGG-3
 
 
 
; 1267, 5
 
 
 
-CTGCTGCAGGAAGGTCT-
GCTC-3
 
 
 
; 2152, 5
 
 
 
-TTGGCTGGGCTCCTGCTGATC-3
 
 
 
;
2153, 5
 
 
 
-CTGCATGGACTCATTCTTCCC-3
 
 
 
; and 2154, 5
 
 
 
-
TTCTCCTGCTTAGAATCATCC-3
 
 
 
.
 
Histochemistry and Fluorescence Microscopy. 
 
For histochemistry,
spleens were removed, embedded in OCT, frozen in liquid nitro-
gen, and kept at 
 
 
 
80
 
 
 
C until sectioning. 10-
 
 
 
m cryosections were
prepared and stored at 
 
 
 
80
 
 
 
C until use. Sections were fixed for 10
min at room temperature with acetone and washed five times with
PBS. After blocking (10% FCS in PBS, 30 min at room tempera-
ture), sections were incubated with ER-TR9 antibody for 1 h at
room temperature, washed, and stained with Vectastain ABC Elite
kit for horseradish peroxidase before being washed again and de-
veloped using a DAB kit (Vectastain). Sections were washed and
mounted with VectaMount. For fluorescence analysis, sections
were fixed and blocked as described before, incubated with the pri-
mary antibody (ER-TR9) for 1 h at room temperature, washed,
and stained with affinity-purified, biotin-conjugated rabbit anti–rat
immunoglobulin for 1 h at room temperature. After washing, the
sections were incubated with Texas red–conjugated streptavidin
(BioMeda) for 1 h at room temperature. Biotin-conjugated anti-
CD11b (clone M1/70; BD Biosciences) or FITC-conjugated anti–
MOMA-1 (Serotec) was also included at this point if appropriate
for double staining. Sections were washed in PBS and mounted
with Vectashield (Vectalabs). Visualization was performed using an
MRC1024 confocal microscope (Bio-Rad Laboratories).
 
Inoculation with Dextran–Alexa Fluor 488. 
 
Mice were inocu-
lated into the tail vein with PBS containing 200 
 
 
 
g of dextran–
Alexa Fluor 488 (molecular weight of 10,000; Molecular Probes).
Coinoculation in the presence of 5% carbon particles (Indian ink)
was also performed. After 2 h, the mice were killed; spleen was re-
moved and embedded in OCT compound; and sections were pre-
pared as described before. Visualization was performed using an
MRC1024 confocal microscope (Bio-Rad Laboratories) or an Ax-
ioplan fluorescence microscope (Carl Zeiss MicroImaging, Inc.).
 
Phosphorylcholine (PC)-specific ELISA. 
 
96-well plates were
coated with 25 
 
 
 
g/ml PC conjugated to bovine sera albumin
(Biosearch Technologies) overnight at 4
 
 
 
C. Plates were blocked
with PBS/10% FCS and washed, and serial dilutions of serum
were incubated overnight at 4
 
 
 
C. A positive control (pooled se-
rum from seven wild-type mice 14 d after immunization with
Pneumovax II; Aventis-Pasteur MSD) was included. Detection
was performed using a biotinylated goat anti–mouse immuno-
globulins (BD Biosciences). Horseradish peroxidase streptavidin
(ICN Biomedicals) activity was revealed by 2,2
 
 
 
-azino-bis(3-eth-
ylbenzthiazoline-6-sulfonic acid) substrate (Sigma-Aldrich). Plates
were read at 405 nm. Antibody titres were calculated relative to
the positive control and compared using an unpaired Student’s 
 
t
 
test (Welch corrected).
 
Bacteria. S.  pneumoniae
 
 type 2 strain D39 and type 14 pro-
vided by J.S. Brown (Imperial College School of Medicine, Lon-
don, England) and D. Goldblatt (University College Hospital,
London, England) were cultured overnight on blood agar plates
(5% CO
 
2
 
, 95% air, 37
 
 
 
C), inoculated into Todd-Hewitt broth
(Oxoid Ltd.), supplemented with 0.5% yeast extract (Oxoid
Ltd.), cultured for 4–5 h, washed, and resuspended at 10
 
9
 
 CFU/
ml (estimated by OD
 
660
 
 
 
 
 
 1); aliquots were stored at 
 
 
 
70
 
 
 
C and
made up in sterile PBS for use. Their concentration was verified
by serial dilution and culture on blood agar plates.
 
S. pneumoniae Peritonitis.
 
Groups of 10–12 male or female,
age-matched control and SIGN-R1
 
   
 
 mice (8–12 wk of age)
were inoculated intraperitoneally with 200 
 
 
 
l of PBS containing 
 
S.
pneumoniae
 
. Mice were observed at least every 6 h for the first 72 h
and every 8 h until 96 h, and daily thereafter. During observation,
mice were scored by a blinded observer for the presence or absence
of physical signs of progressive sepsis in mice. Sickness was scored
according to the presence of piloerection (1 point), plus hunched
posture (2 points) and lack of spontaneous movement (3 points).
Mice that became moribund were considered to have reached the
end point of the experiment and were killed. Tail bleeds were per-
formed at 26 or 30 h after infection, and blood was cultured for
bacterial growth for 24 h. Survival data was analyzed using the
Kaplan-Meier graphs and Log rank tests. All animal experiments
were performed in accordance with UK Home Office regulations.
 
Phagocytosis Assay.  S. pneumoniae
 
 type 2 was cultured to log
phase in Todd-Hewitt broth with 0.5% yeast extract (Oxoid
Ltd.), heat inactivated at 60
 
 
 
C for 1 h, and labeled with FITC
(Sigma-Aldrich). FITC-labeled 
 
S. pneumoniae
 
 were incubated in
PBS or a 1-in-10 dilution of heat-inactivated nonimmune serum
at 37
 
 
 
C for 1 h before washing. Nonimmune serum used for op-
sonization was taken from 2–10 control or age-matched SIGN-
R1
 
   
 
 mice. Peritoneal macrophages or RAW-297 cells were
adhered to plastic, and aliquots of serum-opsonized or nonop-
sonized FITC-labeled pneumococci were added at 4
 
 
 
C (to assess
binding) and 37
 
 C (to assess phagoctyosis) for 30 min. Adhered
macrophages were washed, harvested, and analyzed by flow cy-
tometry (FACScalibur; Becton Dickinson) as described previ-
ously (32). Peritoneal macrophages were identified by scatter
characteristics and Mac-1 staining. The percentage of FITC posi-
tive macrophages was used as a measure of phagocytosis. Dupli-
cate or triplicate wells were processed for each serum sample, and
results were compared using the Student’s t test.
Binding Assay.  SIGN-R1 or control vector transduced
NIH3T3 fibroblasts (28) were incubated with FITC-labeled S.
pneumoniae type 2 at 4 C for 1 h. Samples were washed and ana-
lyzed by flow cytometry (FACScalibur; Becton Dickinson). The
percentage of FITC positive cells and the geometric mean fluo-
rescence were used as a measure of pneumococcal binding. Trip-SIGN-R1 Protects against Lethal Pneumococcal Infection 1386
licate wells were processed, and results were compared using the
Student’s t test.
Inoculation with FITC-labeled S. pneumoniae.  Mice were in-
oculated into the tail vein with PBS containing 107 FITC-labeled
S. pneumoniae. After 30 min, the mice were killed; spleens were
removed and embedded in OCT compound; and sections were
prepared as described before. Counterstaining with biotin-conju-
gated MARCO antibody (Serotec) and Texas red–conjugated
streptavidin (BioMeda) was performed as described before, to de-
lineate MZMs. Visualization was performed using an MRC1024
confocal microscope (Bio-Rad Laboratories).
Results
Cloning of Mouse SIGN-R1 and Inactivation of the Mouse
SIGN-R1 Gene. A full-length mouse SIGN-R1 cDNA
was generated using primers designed from the mouse
SIGN-R1 genomic sequence and cross-referenced to the
human DC-SIGN sequence. The clone encoded a type II
transmembrane protein with an extracellular domain con-
sisting of a neck region made up of four repeats of 28 amino
acids (aa) and a CRD (Fig. 1, a and b). The overall aa se-
quence encoded by mouse SIGN-R1 showed  40% se-
quence identity to human DC-SIGN and DC-SIGNR.
However, more significantly, the CRD of mouse SIGN-R1
showed  75% identity to the CRD of human DC-SIGN
and DC-SIGNR, and 42% identity to the CRD of mouse
CD23. Within the CRD, the residues defining mannose-
binding specificity are conserved between mouse SIGN-R1
and human DC-SIGN as are the residues required for cal-
cium-dependent binding of carbohydrates, features that are
also shared with mouse CD23 (12). During the course of
our work, a family of five SIGN-related genes were charac-
terized as mapping to mouse chromosome 8 close to the
CD23 gene (16). This juxtaposition to CD23 is analogous to
Figure 1. Inactivation of the mouse SIGN-R1 gene by homologous recombination. (a) Structure of the human DC-SIGN locus. (b) Structure of the mouse
SIGN-R1 locus, the targeting vector, and the predicted homologous recombination event are shown. NeoR, neomycin resistance cassette; TK, thymidine
kinase cassette; B, BamHI. (c) RT-PCR analysis of SIGN-R1 expression. RNA was prepared from splenocytes and PCR was performed.    , SIGN-R1   .
(d) RT-PCR analysis of SIGN-R1 expression using PCR primers throughout the cDNA to verify gene deletion. (1) Wild-type. (2) SIGN-R1   .
(3) Wild-type. (4) SIGN-R1   . (e) Staining with ER-TR9 (anti–SIGN-R1) monoclonal antibody using horseradish peroxidase detection. (f) Co-staining
with ER-TR9 monoclonal antibody (Texas red) and MOMA monoclonal antibody (FITC) (identifying marginal metallophilic macrophages). Original
magnification, 10.Lanoue et al. 1387
that observed in human where CD23, DC-SIGN, and DC-
SIGNR are all closely linked within a 85-kb region on
chromosome 19p13 (12, 13). Little is known about the bio-
logical significance of any of these SIGN-related molecules.
To study the in vivo roles of mouse SIGN-R1 in the
development of immune responses, we have generated
SIGN-R1    mice using gene targeting (Fig. 1 b). The
correct insertion of this construct would result in the dele-
tion of nucleotides encoding aa 215–232 in exon 8. Mouse
SIGN-R1    mice were healthy and displayed no overt
phenotypic abnormalities and, as detected by flow cytome-
try, the immune cell composition appeared normal (un-
published data). Analysis of the SIGN-R1    mice failed
to detect SIGN-R1 RNA transcripts from spleen cells us-
ing reverse transcriptase–polymerase chain reaction assays,
though SIGN-R1 RNA was readily detected in the spleens
of wild-type mice (Fig. 1 c). To verify that gene disruption
had ablated SIGN-R1 transcription, we designed PCR
primer pairs throughout the coding region (Fig. 1 d) and
RT-PCR analysis failed to detect a SIGN-R1–specific
product in RNA prepared from SIGN-R1    splenocytes
using any of the PCR primer pairs. In contrast, all PCR
products were detected in RNA prepared from wild-type
splenocytes (Fig. 1 d). Analysis of transcripts for SIGN-R3,
which maps to within  100 kb of SIGN-R1 (16) and is
also expressed in the spleen, showed normal expression lev-
els in SIGN-R1    mice when compared with wild-type
controls (unpublished data). These data demonstrate that
interruption of the SIGN-R1 sequence has not resulted in
the production of aberrant SIGN-R1 transcription prod-
ucts that might lead to truncated SIGN-R1 protein or the
disruption of a neighboring SIGN-R gene. To corroborate
these results, we used antibody staining to assess the cell
surface expression of SIGN-R1. Recently, it has been
demonstrated that the monoclonal antibody ER-TR9,
which has been used previously as a specific MZM marker
(22), recognizes mouse SIGN-R1 (33). Therefore, to ver-
ify the absence of SIGNR1 expression from the cell sur-
face, spleen sections were stained with ER-TR9. As shown
in Fig. 1 e, wild-type spleen sections display clear ER-TR9
staining of cells in the MZ, whereas no staining is observed
in sections prepared from SIGN-R1    spleen. Co-staining
with the fluorescently labeled antibodies ER-TR9 and
MOMA (which recognizes marginal metallophilic mac-
rophages of the MZ; reference 34) confirmed that SIGN-
R1 expression has been deleted in our mice (Fig. 1 f).
MZMs from SIGN-R1    Mice Fail to Take Up the
Polysaccharide Dextran. MZMs play a central role in the
removal of TI-2 antigens, and previous studies using ER-
TR9 and a polyclonal rabbit anti–SIGN-R1 antibody (33)
have reported that these antibodies block the uptake of
polysaccharides such as Ficoll (26) and dextran (33) by
MZMs. To test whether SIGN-R1    mice had a deficit in
TI-2 polysaccharide uptake, we injected wild-type and
SIGN-R1    mice intravenously with ALEXA-conjugated
dextran. After 2 h, spleen sections were prepared and the
presence of ALEXA-dextran was determined by micros-
copy. As expected, ALEXA-dextran was visualized in the
MZs of wild-type mice (Fig. 2, a, c, e, and g). In contrast,
we were unable to detect ALEXA-dextran uptake in the
SIGN-R1    mice (Fig. 2, b, d, f, and h).
To confirm that MZMs were still present in the SIGN-
R1    mice, and capable of phagocytosis, we coinjected
Figure 2. Analysis of MZMs and ALEXA-dextran uptake in the
spleens of wild-type (WT) and SIGN-R1    mice. (a and b) ALEXA-
dextran (Dex, green) localized to the MZs in spleen sections 2 h after i.v.
inoculation. (c and d) Spleen sections demonstrating ALEXA-dextran uptake
counterstained with anti-CD11b (Texas red). (e and f) Spleen sections
demonstrating ALEXA-dextran uptake counterstained with ER-TR9 anti-
body (anti–SIGN-R1; Texas red). (g and h) Spleen sections showing results
of coinoculation with ALEXA-dextran (green) and Indian ink (black
spots). (i and j) Spleen sections demonstrating anti-MARCO antibody
(FITC) staining of MZM. All original magnifications,10.SIGN-R1 Protects against Lethal Pneumococcal Infection 1388
wild-type and SIGN-R1    mice with Indian ink, which
has been shown to be taken up specifically by MZMs (35),
and ALEXA-dextran. As shown in Fig. 2 (g and h), we de-
tected Indian ink uptake in both the wild-type and SIGN-
R1    mice, indicating that MZMs remain in the SIGN-
R1    mice, but are specifically unable to mediate the uptake
of ALEXA-dextran. Double-staining with ER-TR9 and
MARCO (a marker of MZM; reference 23) results in con-
vergent staining of the MZMs (reference 27 and unpublished
data). As we detected normal staining with MARCO in
the spleens of both wild-type and SIGN-R1   , this im-
plies that SIGN-R1 is not necessary for normal MZM de-
velopment (Fig. 2, i and j). These data demonstrate that
SIGN-R1 is not required for the development or localiza-
tion of MZMs, but is specifically required for the binding
of dextran, a prototypical TI-2 antigen. It is noteworthy
that, in the absence of SIGN-R1, we did not detect any
compensatory uptake of ALEXA-dextran by MZ B cells,
DCs, or reticular cells.
SIGN-R1    Mice Succumb to Sublethal S. pneumoniae In-
fection.  TI-2 antigens are highly represented on gram-
positive bacteria such as S. pneumoniae. These bacteria are
important human and mouse pathogens causing pneumo-
nia, meningitis, peritonitis, and septicemia. To test whether
SIGN-R1 is functionally important during infection with
S. pneumoniae, we infected wild-type and SIGN-R1   
mice with a sublethal intraperitoneal dose of the virulent S.
pneumoniae serotype 2. Less than 18% of the SIGN-R1   
mice survived infection as compared with  60% of wild-
type mice (P   0.005; Fig. 3 a). The survival curves also
demonstrate that the absence of SIGN-R1 results in more
rapid mortality. Although 90% of the wild-type mice were
alive at 48 h, only 20% of the SIGN-R1    had survived
(Fig. 3 a). These data were corroborated by the sickness
scores collected during the course of infection, which
clearly demonstrated that the onset of clinically apparent
disease occurred more rapidly in SIGN-R1    mice than
in controls (Fig. 3, b and c). Strikingly, SIGN-R1    mice
showed persistent septicemia after infection, compared
with controls. At 30 h after infection, 95% of the SIGN-
R1    mice had circulating bacterial loads of  25   103
CFU/ml of blood, whereas only 10% of wild type had sim-
ilar levels of circulating bacteria, and 50% had no detectable
bacteria (Fig. 3 d). To exclude any possibility that these re-
sults arose due to strain background effects, we have veri-
fied these data in preliminary experiments using SIGN-
R1    mice and wild-type mice generated by backcrossing
for six generations to the C57BL/6 background. We found
Figure 3. Absence of SIGN-R1 increases susceptibility to pneumococcal peritonitis. (a) Survival after S. pneumoniae type 2 infection. SIGN-R1   
mice (n   12) or control mice (n   12) were inoculated intraperitoneally with 103 S. pneumoniae type 2. SIGN-R1    have reduced survival (P   0.005). The
experiment shown is representative of two, and p-values were obtained using a Log rank test. (b and c) Physical signs of illness in mice with pneumococcal
peritonitis. After inoculation with S. pneumoniae (type 2), mice were monitored by a blinded observer for the signs of systemic illness. The presence or absence of
piloerection (1 point), with additional hunched posture (2 points), and lack of spontaneous movement (3 points) was scored in control and SIGN-R1   
mice inoculated with 103 S. pneumoniae at 24 h (b) and 30 h (c). The experiment is representative of two. (d) 30 h after inoculation with S. pneumoniae,
tail bleeds were performed on control (n   12) and SIGN-R1    mice (n   10), and blood was cultured for bacterial growth. More SIGN-R1    mice
were bacteremic (P   0.014); the p-value was obtained using a Fisher’s exact test. (e) Survival after S. pneumoniae type 14 infection. SIGN-R1    mice
(n   10) or control mice (n   10) were inoculated intraperioneally with 105 S. pneumoniae type 14. SIGN-R1    have reduced survival (P   0.018).
Numbers denote individual mice. p-values were obtained using a Log rank test. (f and g) Physical signs of illness in mice with pneumococcal peritonitis.
After inoculation with S. pneumoniae (type 14), mice were monitored by a blinded observer for the signs of systemic illness (as described before). (h) 26 h
after inoculation with S. pneumoniae, tail bleeds were performed on control (n   10) and SIGN-R1    mice (n   10), and blood was cultured for bacterial
growth. More SIGN-R1    mice were bacteremic (P   0.023).Lanoue et al. 1389
100% survival of wild type (n   10) and 40% survival of
SIGN-R1    (n   7) mice 48 h after intraperitoneal infec-
tion with 103 S. pneumoniae serotype 2, and 90% survival of
wild type (n   10) and 0% survival of SIGN-R1    (n  
7) mice 48 h after intraperitoneal infection with 104  S.
pneumoniae serotype 2, fully validating our earlier findings.
To extend our findings to other S. pneumoniae strains, we
have also performed infections with the less virulent S. pneu-
moniae serotype 14, which has been shown previously to as-
sociate with SIGN-R1 through its capsular polysaccharides
(27). As for S. pneumoniae serotype 2, increased mortality was
also observed in SIGN-R1    mice infected with S. pneumo-
niae serotype 14 when compared with wild-type controls
(Fig. 3 e). This experiment also demonstrated that sickness
scores and bacteremia correlate with survival; those animals
showing the highest bacteremia are the first to display higher
sickness scores and subsequently die (Fig. 3, e–h).
These data clearly demonstrate that SIGN-R1 is impor-
tant for the efficient clearance of S. pneumoniae from infected
mice and that, in the absence of SIGN-R1, mice develop
severe bacteremia leading to rapid and increased mortality.
Impaired Bacterial Clearance Is Not Due to Reduced Natu-
ral Antibody.  Although the adaptive antibody response
would not be elicited within the time scale of this S. pneu-
moniae infection, the levels of natural antibody have been
shown to be critical to survival (36). Natural antibodies are
preexisting antibodies found in the sera of naive mice and
are involved in responses to a range of pathogens. Natural
antibodies exist in germ-free mice and these are thought to
be selected by self-antigens (37), though some natural anti-
bodies require the presence of exogenous antigen or gut
flora for their production (38). Natural antibodies have a re-
stricted range of specificities and are generally lower affinity
antibodies against bacterial antigens such as PC and phos-
phatidylcholine (39). They contribute to innate immunity
through the binding of bacteria, facilitating complement ac-
tivation and Fc receptor-mediated clearance, which can lead
to phagocytosis and destruction of the bacterium (40). Both
B-1 and MZ B cells have been shown to generate anti-PC
antibodies, and these natural antibodies can confer protec-
tion against S. pneumoniae infections in mice (36). To assess
whether the inability to clear the infection in SIGN-R1   
mice was due to a defect in their production of natural anti-
bodies, we analyzed the levels of anti-PC antibodies in na-
ive wild-type and SIGN-R1    mice; no significant differ-
ence was found (Fig. 4 a). Furthermore, we would predict
that if SIGN-R1 was altering levels of natural antibody, se-
rum from SIGN-R1    mice might be less efficient at op-
sonizing encapsulated bacteria and promoting Fc receptor-
dependent phagocytosis by cells such as macrophages. To
test this, we used serum from naive SIGN-R1    mice and
wild-type mice to opsonize FITC-conjugated S. pneumo-
niae. These bacteria were incubated with the RAW mouse
macrophage cell line for 30 min. Phagocytosis of bacteria
was measured by flow cytometry, and opsonization with se-
rum from SIGN-R1    mice resulted in a similar propor-
tion of macrophages engulfing bacteria as serum from the
wild-type mice (Fig. 4 b). Similar results were obtained
when peritoneal macrophages from wild-type mice were
used in place of RAW cells (Fig. 4 c).
Impaired S. pneumoniae Recognition by Peritoneal Macro-
phages from SIGN-R1    Mice.  Peritoneal macrophages
are uniquely located to play a crucial role in the defensive re-
sponse to bacterial infection; a recent paper has suggested that
SIGN-R1 expression by peritoneal macrophages may be im-
portant for the recognition of yeast particles (28). Given the
extremely rapid susceptibility of the SIGN-R1    mice to S.
pneumoniae infection, we wished to determine whether S.
pneumoniae recognition by peritoneal macrophages was im-
paired by the absence of SIGN-R1. Initially, we wished to
confirm that SIGN-R1 was binding S. pneumoniae. To test
Figure 4. Absence of SIGN-R1 does not impair natural antibody levels
or opsonization of S. pneumoniae. (a) Natural anti-PC antibody levels in
control and SIGN-R1    mice. Sera from naive WT and SIGN-R1   
mice were assayed for natural antibodies against PC by ELISA. Each point
represents the value from an individual mouse. p-values were determined
using an unpaired Student’s t test (Welch corrected). (b and c) Nonimmune
serum from control and SIGN-R1    mice provide equivalent opsonization.
The RAW-297 macrophage cell line (b) or BALB/c peritoneal macrophages
(c) were incubated at 37 C with FITC-labeled S. pneumoniae opsonized
with heat-inactivated nonimmune serum (NIS) from wild-type or SIGN-
R1    mice, followed by flow cytometric analysis. Phagocytosis is expressed
as percentage of FITC positive cells. Values represent mean of triplicates, the
experiments shown are representative of two, and p-values were obtained
using an unpaired Student’s t test.SIGN-R1 Protects against Lethal Pneumococcal Infection 1390
this, FITC-labeled S. pneumoniae were incubated with retro-
virally transduced NIH3T3 cells expressing SIGN-R1 (28)
or parental NIH3T3 cells. The cells expressing SIGN-R1
bound S. pneumoniae significantly more efficiently than the
parental line, demonstrating that SIGN-R1 binds directly to
S. pneumoniae (Fig. 5 a). We assessed whether binding or
phagocytosis of S. pneumoniae was abnormal in SIGN-R1   
peritoneal macrophages. Peritoneal macrophages were incu-
bated for 30 min with FITC-labeled S. pneumoniae at 4 C to
assess surface binding, or 37 C to assess phagocytosis, before
analysis by flow cytometry. We found that peritoneal mac-
rophages from SIGN-R1    mice were significantly im-
paired (threefold reduction) in their ability to bind S. pneu-
moniae at 4 C (Fig. 5 b). Furthermore, fewer than half as
many macrophages from SIGN-R1    mice phagocytosed
S. pneumoniae at 37 C, compared with controls (Fig. 5 c); in-
ternalization was confirmed by confocal microscopy (Fig. 5
d). This reduction in phagocytosis in SIGN-R1    macro-
phages was proportional to the reduction in surface binding
seen at 4 C (Fig. 5 b), suggesting that the observed reduction
in phagocytosis was secondary to reduced recognition of S.
pneumoniae in the absence of SIGN-R1.
Figure 5. Impaired recognition of
S. pneumoniae by SIGN-R1    peri-
toneal macrophages. (a) S. pneumoniae
bind preferentially to SIGN-R1–
transduced NIH3T3 (SIGNR1) cells
compared with wild-type (WT)
NIH3T3. Cells were incubated for
1 h at 4 C with FITC-labeled pneu-
mococci, washed, and analyzed by
flow cytometry. Values represent the
mean of triplicates, and p-values
were obtained using an unpaired
Student’s t test. (b–d) Pooled perito-
neal macrophages from wild-type
(n   2) or SIGN-R1    mice (n   2)
were incubated for 30 min with
FITC-labeled S. pneumoniae at 4 C
to assess binding (b), or 37 C to assess
phagocytosis (c), followed by flow
cytometric analysis. Binding or phago-
cytosis are expressed as percentage of
FITC positive cells. SIGN-R1 / 
peritoneal macrophages show re-
duced binding and phagocytosis of
S. pneumoniae. Representative FACS
profiles are shown. Values represent
mean of triplicates, the experiments
shown are representative of two, and
p-values were obtained using an un-
paired Student’s t test. (d) Confocal
images of wild-type and SIGN-R1   
peritoneal macrophages labeled with
Mac-1 allophycocyanin after incuba-
tion with FITC-labeled S. pneumoniae
at 37 C for 45 min.Lanoue et al. 1391
Reduced Binding of S. pneumoniae to MZMs in SIGN-R1   
Mice.  Given that SIGN-R1 is necessary for normal bind-
ing of S. pneumoniae by peritoneal macrophages in vitro, we
sought to determine if the same was true of MZMs in vivo
because they have been identified as critical for the uptake of
certain polysaccharide antigens. Live FITC-conjugated S.
pneumoniae were injected intravenously into SIGN-R1   
and wild-type mice and spleen sections were assessed for the
distribution of bacteria. 30 min after administration, S. pneu-
moniae were found localized almost exclusively in the MZs
of the spleens of wild-type mice, with few bacteria detected
in the red pulp (Fig. 6, left). In contrast, in the spleens from
SIGN-R1    mice, S. pneumoniae were no longer restricted
to the MZs, but were disseminated throughout the red pulp
(Fig. 6, right). These results demonstrate that SIGN-R1 is
important in trapping bacteria in the MZ.
Thus, SIGN-R1 is required for the binding and efficient
clearance of S. pneumoniae by macrophages. Absence of
SIGN-R1 leads to impaired trapping of bacteria in the
MZs, increased septicemia, and reduced survival in re-
sponse to streptococcal infection.
Discussion
Here, we have shown that SIGN-R1 is a key receptor re-
quired for innate immunity to the gram-positive pathogen
S. pneumoniae. In the absence of SIGN-R1, SIGN-R1   
mice show markedly increased mortality after infection with
S. pneumoniae. This impaired survival is accompanied by a
failure of the SIGN-R1    mice to eradicate S. pneumoniae
from the blood. In contrast, wild-type animals show rapid
clearance of the infection and show significantly improved
survival. We demonstrate that this failure to clear the bacte-
ria is not due to changes in natural antibody levels, but is
consistent with the observed failure of the SIGN-R1   
MZMs and peritoneal macrophages to bind and conse-
quently phagocytose S. pneumoniae efficiently and, thus, re-
move these bacteria from the circulation. These data provide
the first evidence that SIGN-R1 expressed on macrophages
plays an essential role in host defense against S. pneumoniae
by mediating recognition and clearance of these bacteria.
It has long been recognized that the macrophages of the
MZ are highly phagocytic and are organized strategically
within the spleen to optimize their capacity to filter blood-
borne particles. Lying between the white pulp and the red
pulp, and arranged at the border of the sinus, MZMs were
first characterized by their capacity to recognize and inter-
nalize TI-2 antigens. We demonstrate that SIGN-R1, ex-
pressed on MZMs and macrophages of the peritoneum, is a
key receptor for the recognition and efficient clearance of
pathogenic bacteria such as S. pneumoniae by the innate im-
mune system. It is also noteworthy that, although SIGN-
R1 is a member of a family of SIGN molecules (16–18), its
function in S. pneumoniae clearance is not compensated for
by the other family members.
The germline-encoded PRR recognize antigens on
pathogens that are critical to survival and that do not un-
dergo significant alteration due to evolutionary pressure.
Recent papers have demonstrated, using in vitro assay sys-
tems, that human DC-SIGN and DC-SIGNR have been
commandeered by several human pathogens and used to
facilitate rather than protect against infection (2). Although
the human SIGN molecules appear to represent an immu-
nological liability in some circumstances, our experiments
with SIGN-R1 suggest that SIGN molecules play func-
tionally important roles in the rapid clearance of specific
pathogens by the innate immune system. Our paper clearly
demonstrates for the first time a protective role for a SIGN
family member.
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Figure 6. Impaired S. pneumoniae trapping by SIGN-R1    MZM.
Wild-type (left) and SIGN-R1    (right) mice were injected intrave-
nously with 107 FITC-labeled S. pneumoniae. 30 min later, spleens were
snap frozen, and cryosections were prepared and counterstained with
anti-MARCO antibody (Texas red) to delineate MZMs. Arrows indicate
areas where S. pneumoniae are located in the red pulp and are not restricted to
the MZ. FO, follicles. Original magnification, 10 (top), 20 (bottom).
Representative sections from two mice per group are shown.SIGN-R1 Protects against Lethal Pneumococcal Infection 1392
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